Lightnews — Scholar-powered news

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 28

Can immune signals in blood predict ICI response in early-stage HR+ breast cancer? A new study with contributions from Elizabeth Mittendorf and Eliezer Van Allen links CD8 T cell turnover, IFN activity in B cells & monocyte shifts to outcomes: www.nature.com/articles/s41...

Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients - npj Breast Cancer

npj Breast Cancer - Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients

www.nature.com

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 22

Immune recovery after transplant may rely less on the thymus & more on choosing the right stem cells. A PICI-supported @nature.com study identifies a unique group of blood-forming stem cells that improve immune rebuilding after transplant: www.nature.com/articles/s41...

Kitlo hematopoietic stem cells exhibit distinct lymphoid-primed chromatin landscapes that enhance thymic reconstitution - Nature Communications

Hematopoietic stem cells (HSCs) differentiate into multiple lineages, with such capacity impacted by aging. Here the authors identify Kitlo HSCs as a functionally distinct population that exhibits dis...

www.nature.com

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 16

What if one cell therapy could seed another? A Phase I @nature.com ‬study by @dgsomucla.bsky.social shows HSCs can be engineered to make tumor-targeting T cells—unlocking durable, self-renewing immunity.

www.nature.com/articles/s41...

#CancerImmunotherapy #CellTherapy #TCRT

Human cancer-targeted immunity via transgenic hematopoietic stem cell progeny - Nature Communications

Therapeutic T cells engineered to recognize tumour antigens are frequently short-lived and acquire unfavourable phenotypes in tumours. Here authors show that a tandem approach using autologous T cells...

www.nature.com

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 11

What if tumors helped the immune system destroy them? A new PICI-supported study by @ucsanfrancisco.bsky.social & @washumedicine.bsky.social shows ATG9A-deficient tumors are vulnerable to macrophages. Add Trastuzumab + CSF1Ri? Full regression—no T cells: nature.com/articles/s41...

Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity - Nature Communications

The mechanism of macrophage cytotoxicity against cancer cells requires further illustration. By employing CRISPR screening in CAR-macrophage and cancer cell co-culture system, the authors identify dep...

nature.com

1 1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 8

This form of diabetes affects up to 2% of patients on checkpoint inhibitors — and most require ICU care. The findings point to a path forward. (2/2)

→ www.uclahealth.org/news/release...
→ doi.org/10.1172/jci....

Common autoimmune drug may help reverse immunotherapy-induced diabetes, UCLA study finds

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...

www.uclahealth.org

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 8

Can a common autoimmune drug help reverse a serious side effect of cancer immunotherapy?

A new PICI-supported @uclahealth.org study says maybe yes. JAK inhibitors may prevent or even reverse type 1 diabetes caused by checkpoint inhibitors. (1/2)

1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jul 1

Congratulations to @pelkalab.bsky.social (@gladstoneinst.bsky.social) on receiving the 2025 @aaas.org Martin and Rose Wachtel Cancer Research Award. Her paradigm-shifting work in colorectal cancer is shaping the way we understand and potentially treat solid tumors. www.science.org/doi/10.1126/...

1 2 3

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 27

At #FOCIS2025, PICI President of Research Ira Mellman, PhD, delivered a keynote on how decades of discovery are rapidly becoming durable treatments — from checkpoint inhibitors and dendritic cells to cancer vaccines and engineered T cells.

FOCIS - Federation of Clinical Immunology Societies @focisimmunology.bsky.social · Jun 25

Join us in Salons F-G for the Wednesday night keynote - Dr. Ira Mellman!

#focis2025

1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 24

KRAS mutations are among the most common—and hardest—targets in solid tumors. A new study from @pennmedicine.bsky.social introduces NeoCARs: T cells engineered to target mutant KRAS (G12V) via pMHC. IL-12 armoring + TCR knockout boost potency and safety: doi.org/10.1016/j.cc...

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 18

Thrilled to celebrate our CEO, @‪drkarenknudsen.bsky.social‬ as a 2025 CNBC Changemaker! From NIH research to the American Cancer Society to leading PICI, her mission: get innovation to those who need it most. Learn more:
www.cnbc.com/2025/06/18/c...
#Changemaker #CancerResearch

CEO of Sean Parker's breakthrough cancer drug institute on leading new race for cure

Karen Knudsen is leading Sean Parker's cancer immunotherapy incubator where philanthropy and venture capital meet.

www.cnbc.com

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 17

120+ minds. 3 days. 1 mission. At the PICI Spring Scientific Retreat, we aligned on what’s next in cancer immunotherapy. From AI to predictive biomarkers & smarter cell therapies, we’re moving breakthroughs from bench to bedside with urgency & purpose. Full recap: www.parkerici.org/the-latest/d...

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 17

PICI Investigator @judithagudo.bsky.social, PhD, was recognized with the 2025 CRI Lloyd J. Old STAR Award, one of immuno-oncology’s highest honors from the Cancer Research Institute (CRI). Congratulations, Dr. Agudo!

www.cancerresearch.org/media-room/2...

1 4

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 14

“Why stop now, when we haven’t yet realized immunotherapy’s full potential?” In @natrevdrugdiscov.nature.com, Ira Mellman, PhD, President of Research at PICI, shares what’s next in Immunotherapy — from curative cell therapies to smarter T cells.

🔗 nature.com/articles/d41...

#Immunotherapy #Cancer

2 3

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 13

Congratulations to Anusha Kalbasi, MD, PICI Investigator at @stanfordmedicine.bsky.social, on receiving the 2025 CRI Lloyd J. Old STAR Award. By advancing cell therapies for tough cancers, he is translating science into hope for patients who need it most.

www.cancerresearch.org/media-room/2...

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 11

At #ASCO25, PICI CEO @drkarenknudsen.bsky.social spoke with @endpts.com ‬about how PICI is accelerating trials, investing in AI & protecting progress as funding comes under threat.

→ Full conversation: events.endpts.com/asco25/on-de...

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 7

Celebrating Dr. Elizabeth Mittendorf, Co-Director of the PICI Center at Dana-Farber, on her election as @ASCO President for 2026–27! Her work is advancing cancer care.
🎧 Hear more: podcasts.apple.com/us/podcast/f...

🔗 Read more: www.onclive.com/view/dr-mitt...

#ASCO #Immunotherapy #PICIProud

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 4

THIS MORNING: PICI CEO @drkarenknudsen.bsky.social joins @endpts.com at #ASCO2025 to discuss PICI’s evolving model and the imperative to align research, policy and investment with the realities facing patients today.

Register and watch live at 10:35 am CDT: events.endpts.com/asco25

2

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · Jun 3

Read this Endpoints article for insights on multiple glioblastoma study findings presented at #ASCO2025 with key contributions from Marcela Maus, MD, PhD (Massachusetts General Hospital), as well as Carl June, MD and Donald O’Rourke, MD (‪@pennmedicine.bsky.social)

Endpoints News @endpts.com · Jun 3

#ASCO25: Promising advances in cell therapies to treat aggressive brain cancer. The trials are small, but the data revealed last weekend is encouraging where other treatments have shown little effect.
endpoints.news/asco25-brain...

At ASCO, cell therapies for deadly form of brain cancer make early strides

Early studies of cell therapies for brain cancers show long-term survival in select patients, including promising results from City of Hope, IN8Bio, UPenn & MGH, while others saw rapid progression.

endpoints.news

Reposted by Parker Institute for Cancer Immunotherapy (PICI)

Dana-Farber Cancer Institute @danafarber.bsky.social · Jun 1

David Barbie, MD, presents insights from the phase 3 ADRIATIC trial, examining clinical and molecular traits of early progressors and long-term survivors using durvalumab vs placebo after chemoradiotherapy in limited-stage small-cell lung cancer. #ASCO25

2 4

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 31

Dr. Knudsen's contributions include over 300 peer-reviewed publications and paradigm-shifting discoveries in prostate cancer research.

Congratulations, @drkarenknudsen.bsky.social, and thank you for your unwavering commitment to ending cancer's devastating impact. #PICIatASCO #ASCO2025 (3/3)

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 31

Dr. Knudsen bridges academia, industry & philanthropy, driving innovations from lab to clinic. With leadership roles at Sidney Kimmel Cancer Center, @americancancersoc.bsky.social & PICI, @drkarenknudsen.bsky.social al exemplifies how bold science & visionary leadership can accelerate cures. (2/3)

1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 31

Today at #ASCO2025, @drkarenknudsen.bsky.social, CEO of the Parker Institute for Cancer Immunotherapy, receives the Allen S. Lichter Visionary Leader Award—recognizing a career dedicated to turning bold research into real patient impact.

9:45 AM–12:00 PM CDT | Hall B1
parkerici.org/asco2025 (1/3)

parkerici.org

1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 31

With 300+ publications and a commitment to accelerating therapies, @drkarenknudsen.bsky.social has built bridges across academia, industry and philanthropy.

Thank you for your dedication to ending cancer’s devastating impact.

🕘 Sat, 9:45 AM CT | Hall B1
🔗 www.parkerici.org/the-latest/a...

ASCO 2025: In a Defining Era for Oncology, PICI Drives Patient Impact Forward - Parker Institute for Cancer Immunotherapy

PICI’s contributions at ASCO 2025 span more than 50 presentations, including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only...

www.parkerici.org

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 31

Tomorrow at #ASCO2025, @drkarenknudsen.bsky.social, CEO of PICI, will receive the Allen S. Lichter Visionary Leader Award—one of oncology’s highest recognitions.

From leading the American Cancer Society to advancing @parkerici.bsky.social, her work exemplifies bold science and strategic leadership.

1

Parker Institute for Cancer Immunotherapy (PICI) @parkerici.bsky.social · May 30

Targets EGFRvIII & deploys TEAM antibodies at wild‑type EGFR—early traction against GBM heterogeneity.

Explore more PICI Network highlights: www.parkerici.org/the-latest/a...
#PICIatASCO #CancerImmunotherapy (2/2)